Haisco Pharmaceutical Group Co Ltd
SZSE:002653
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.62
39.64
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co Ltd
Cash from Operating Activities
Haisco Pharmaceutical Group Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
|
Cash from Operating Activities
¥513m
|
CAGR 3-Years
708%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Operating Activities
¥3.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cash from Operating Activities
¥1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
17%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Operating Activities
¥7.9B
|
CAGR 3-Years
39%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Operating Activities
¥4.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash from Operating Activities
-¥615.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Haisco Pharmaceutical Group Co Ltd
Glance View
Haisco Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products and medical equipment. The company is headquartered in Shannan, Xizang and currently employs 4,247 full-time employees. The company went IPO on 2012-01-17. The Company’s main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The firm distributes its products in domestic market.
See Also
What is Haisco Pharmaceutical Group Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
513m
CNY
Based on the financial report for Sep 30, 2024, Haisco Pharmaceutical Group Co Ltd's Cash from Operating Activities amounts to 513m CNY.
What is Haisco Pharmaceutical Group Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
0%
Over the last year, the Cash from Operating Activities growth was 71%. The average annual Cash from Operating Activities growth rates for Haisco Pharmaceutical Group Co Ltd have been 708% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
